Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
Full Phase 2 Explore-CKD results for lorundrostat were published in Kidney International, with the trial meeting its primary endpoint in 59 patients with uncontrolled hypertension, CKD and albuminuria. Lorundrostat 25 mg once daily delivered a 7.5 mmHg placebo-adjusted systolic BP reduction at week four (p=0.0024), plus a 25.6% placebo-adjusted UACR reduction and a 41.5% drop in serum aldosterone. Safety was consistent with prior trials.
Key figures
- Drug Name
- lorundrostat
- Phase Of Trial
- Phase 2
- Sites
- 42
- Participants
- 59
- P value primary
- 0.0024
- Aldosterone reduction
- 41.5%
- Sbp reduction active mmhg
- 9.3
- Sbp reduction placebo mmhg
- 1.8
- Uacr reduction placebo adjusted
- 25.6%
- Placebo adjusted sbp reduction mmhg
- 7.5
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.